Project Total: $274,000; Based on our prospective adverse drug reaction (ADR) registry:1
* 15% of medical admissions to Tasmanian public hospitals in elderly patients were ADR-related,
* 89% were preventable,
* 17% patients had a repeat ADR within 12 months, and
* One third of patients with repeat ADRs experienced the same ADR caused by the same medications.
From this clinical registry, we developed and validated an ADR risk prediction score (PADR-EC).2
We hypothesise that ADR risk stratification during hospitalisation and communication of this risk, together with recommendations that target the specific risk factors identified, to GPs at discharge will reduce the risk of ADR-related hospitalisation.
Design: A randomised controlled trial (RCT) at the Royal Hobart Hospital, the major public hospital in Tasmania.
Population: Over 12-months, 1000 patients ≥65 years with unplanned admissions to medical wards will be recruited and randomly allocated to intervention or control groups.
Intervention: A researcher will perform an ADR risk assessment using the PADR-EC Score,2 which is the sum of points assigned to 5 independent predictors of ADR-related hospitalisation. Based on the PADR-EC Score and the specific risk factors identified, recommendations to reduce the risk of ADRs will be determined.
Recommendations will relate to:
* post-discharge medication management services,
* monitoring of specific parameters/medications, and
* de-prescribing strategies.
The PADR-EC Score and recommendations will be communicated to the patient and clinical team during hospitalisation, and the patient's GP, alongside the usual information, in the electronic discharge summary.
Control: Usual hospital care, with GPs receiving the standard discharge summary.
Follow up: All participants will be followed by the research team for 12-months to identify ADRs (including their management and outcome) and health services received.
Outcomes: ADR-related hospitalisation (primary); ADRs requiring hospital treatment, change in therapy or specific treatment (secondary). The study will be powered to detect a 5% difference in the primary outcome Funded by: Hospitals Contribution Fund Research Foundation - HCF - Grant-Health Services Research Program ($274,000); University of Tasmania.
GRANT
ReMInDAR Trial Reducing Medicine Induced Deterioration and Adverse Reactions Trial
1 May 2018 - 31 Mar 2021
People funded by this grant:
Bereznicki L,
Roughead L,
Pratt N,
Parfitt G,
Cousins J
Project Total: $2,847,927; This randomised controlled trial will assess a pharmacist led intervention to reduce medicine induced deterioration and adverse reactions. Medicine induced deterioration encompasses the spectrum of side effects that are frequently not recognised as medication related but are misattributed as geriatric syndromes, frailty or changes due to aging?. The aim of the service is to enable early identification of signs and symptoms of medicine- induced deterioration so that worsening frailty and subsequent adverse events, such as injurious falls, fractures and delirium are prevented. In implementing the service, the pharmacist will use a suite of validated tools to assist in the detection of signs and symptoms of medicine-induced deterioration. The validated tools will encompass assessments to monitor changes in cognition, change in 24-hour movement behavior, including sleep, as well as grip strength. In addition, pharmacists will assess the potential for adverse medicine events via review of the resident care assessment record and through patient or carer reported changes in health since the medicine regimen was changed. The pharmacist service will be compared with usual care. The trial, involving 500 patients will take place in aged-care facilities in South Australia and Tasmania. Evaluation will encompass health program, clinical and economic evaluation. The expected clinical outcome is a reduction in medication-induced deterioration, as measured by change in frailty score. Adverse events will be measured as a secondary outcome. The cost- effectiveness evaluation will assess cost per adverse event avoided. Funded by: Department of Health, Disability and Ageing (Cth) - Pharmacy Trial Program (Tranche 2) ($2,847,927); University of Tasmania.